Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 5 |
| List of Tables | 6 | 1 |
| List of Figures | 6 | 1 |
| Introduction | 7 | 1 |
| Global Markets Direct Report Coverage | 7 | 1 |
| E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Overview | 8 | 1 |
| Therapeutics Development | 9 | 4 |
| E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Products under Development by Stage of Development | 9 | 1 |
| E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Products under Development by Therapy Area | 10 | 1 |
| E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Products under Development by Indication | 11 | 2 |
| E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Pipeline Products Glance | 13 | 2 |
| Late Stage Products | 13 | 1 |
| Early Stage Products | 14 | 1 |
| E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Products under Development by Companies | 15 | 4 |
| E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Products under Development by Universities/Institutes | 19 | 2 |
| E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Therapeutics Assessment | 21 | 6 |
| Assessment by Monotherapy/Combination Products | 21 | 1 |
| Assessment by Mechanism of Action | 22 | 1 |
| Assessment by Route of Administration | 23 | 2 |
| Assessment by Molecule Type | 25 | 2 |
| E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Companies Involved in Therapeutics Development | 27 | 7 |
| Aileron Therapeutics, Inc. | 27 | 1 |
| Amgen Inc. | 28 | 1 |
| Ascentage Pharma Group Corporation, Ltd. | 29 | 1 |
| Daiichi Sankyo Company, Limited | 30 | 1 |
| F. Hoffmann-La Roche Ltd. | 31 | 1 |
| Merck &Co., Inc. | 32 | 1 |
| Novartis AG | 33 | 1 |
| E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Drug Profiles | 34 | 30 |
| ALRN-6924 Drug Profile | 34 | 2 |
| AM-7209 Drug Profile | 36 | 1 |
| AMG-232 Drug Profile | 37 | 1 |
| APG-115 Drug Profile | 38 | 1 |
| ATSP-7041 Drug Profile | 39 | 2 |
| CGM-097 Drug Profile | 41 | 1 |
| DS-3032 Drug Profile | 42 | 1 |
| DS-5272 Drug Profile | 43 | 1 |
| HDM-201 Drug Profile | 44 | 1 |
| idasanutlin Drug Profile | 45 | 2 |
| ISA-27 Drug Profile | 47 | 1 |
| MI-888 Drug Profile | 48 | 1 |
| MK-8242 Drug Profile | 49 | 1 |
| MMRi-64 Drug Profile | 50 | 1 |
| nutlin-3 Drug Profile | 51 | 1 |
| R-xxx Drug Profile | 52 | 1 |
| RG-7775 Drug Profile | 53 | 1 |
| RO-8994 Drug Profile | 54 | 1 |
| Small Molecule 1 to Inhibit MDM2 for Oncology Drug Profile | 55 | 1 |
| Small Molecule 2 to Inhibit MDM2 for Oncology Drug Profile | 56 | 1 |
| Small Molecule 3 to Inhibit MDM2 for Oncology Drug Profile | 57 | 1 |
| Small Molecules to Inhibit MDM2 and MDM4 for Acute Lymphoblastic Leukemia Drug Profile | 58 | 1 |
| Small Molecules to Inhibit MDM2 for Breast Cancer Drug Profile | 59 | 1 |
| Small Molecules to Inhibit p53-hdm2 for Oncology Drug Profile | 60 | 1 |
| Small Molecules to Inhibit p53-MDM2 Interaction for Cancer Drug Profile | 61 | 1 |
| Small Molecules to Target Hdm2 for Proliferative Vitreoretinopathy Drug Profile | 62 | 1 |
| Vaccine to Target CD105, Yb-1, SOX2, CDH3 and MDM2 for Breast Cancer Drug Profile | 63 | 1 |
| E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Dormant Projects | 64 | 3 |
| E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Discontinued Products | 67 | 1 |
| E3 Ubiquitin Protein Ligase Mdm2 (Double Minute 2 Protein or Hdm2 or Oncoprotein Mdm2 or p53 Binding Protein Mdm2 or MDM2 or EC 6.3.2.) Featured News &Press Releases | 68 | 4 |
| Feb 12, 2015: Aileron Therapeutics Initiates Phase 1 Cancer Study of ALRN-6924 in Advanced Hematologic and Solid Malignancies with Wild Type p53 | 68 | 1 |
| Dec 05, 2014: Roche to present clinical data on RG-7388 at ASH | 69 | 1 |
| Aug 15, 2013: Aileron Therapeutics Publishes Data Demonstrating ATSP-7041 as First-in-class p53 Pathway Re-activator for the Treatment of Solid and Hematologic Cancers | 69 | 1 |
| Nov 07, 2012: Aileron Therapeutics Presents New Data On Stapled Peptide Oncology Program At EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics | 70 | 1 |
| Oct 31, 2012: Aileron Therapeutics To Present Data On Stapled Peptides At Upcoming Scientific Conferences And Industry Events | 71 | 1 |
| Appendix | 72 | 2 |
| Methodology | 72 | 1 |
| Coverage | 72 | 1 |
| Secondary Research | 72 | 1 |
| Primary Research | 72 | 1 |
| Expert Panel Validation | 72 | 1 |
| Contact Us | 72 | 1 |
| Disclaimer | 73 | 1 |